IRIS

The development of targeted therapies increases treatment options for metastatic castration resistant prostate cancer (mCRPC) patients. There is a need for strong predictive and prognostic signatures to guide physicians in treating mCRPC patients. In this review we unravel the possible actionability in the AR pathway, PI3K AKT signaling, and DNA repair pathways. Additionally, we make recommendations on biomarker trial design, and the clinical use of this new type of data.

Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer / Devlies, Wout; Eckstein, Markus; Cimadamore, Alessia; Devos, Gaëtan; Moris, Lisa; Van den Broeck, Thomas; Montironi, Rodolfo; Joniau, Steven; Claessens, Frank; Gevaert, Thomas. - In: CELLS. - ISSN 2073-4409. - 9:11(2020), p. 2494. [10.3390/cells9112494]

Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer

Alessia Cimadamore;Rodolfo Montironi;
2020-01-01

Abstract

The development of targeted therapies increases treatment options for metastatic castration resistant prostate cancer (mCRPC) patients. There is a need for strong predictive and prognostic signatures to guide physicians in treating mCRPC patients. In this review we unravel the possible actionability in the AR pathway, PI3K AKT signaling, and DNA repair pathways. Additionally, we make recommendations on biomarker trial design, and the clinical use of this new type of data.
2020
CELLS
1.1 Articolo in rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11566/285507
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 12
social impact